Navigation Links
Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
Date:10/11/2007

ARLINGTON, Va., Oct. 11 /PRNewswire/ -- The American Association of Health Freedom and the International Hyperbaric Medical Association announced today that physician-researchers at the Baromedical Research Institute and Louisiana State University School of Medicine, New Orleans have reported the successful treatment of chronic traumatic brain injury (TBI). The findings, published in Brain Research (2007 Oct 12;1174:120-9), are purportedly the first-ever demonstration of improvement of chronic brain injury in animals. The treatment involved a new application and drug dosage of hyperbaric oxygen therapy. Hyperbaric oxygen therapy has been applied to diving injuries, carbon monoxide poisoning, "flesh-eating bacteria," and chronic wounds. Application to chronic brain injury is controversial. This demonstration is a landmark achievement that reverses 100 years of neurology and the institutionalized belief that chronic brain injury in untreatable. It has significant implications for the treatment of chronic human traumatic brain injury (TBI) such as for current U.S. military veterans.

Lead author, Paul G. Harch, M.D., Clinical Assistant Professor, Director of the LSU School of Medicine Hyperbaric Medicine Fellowship in New Orleans, and author of recently published The Oxygen Revolution (Hatherleigh Press, NY), said that he made this discovery when he first applied HBOT to divers with a disabling form of "the bends," brain decompression illness. Harch noticed that the traditional application of a single HBOT to freshly injured divers did not result in the immediate cure described by the U.S. Navy. Instead, divers from the Gulf of Mexico presented days to weeks after their injury and required much more HBOT at a lower pressure. Eventually, he realized that they were treating more chronic forms of brain injury since the bubbles had long passed through the divers' brains. Harch and colleagues applied this lower dose of HBOT to patients with other forms of chronic brain injury, including trauma, cerebral palsy, autism, toxic brain injury, dementia, and multiple other diagnoses.

Harch stated that when he presented this human case experience at scientific meetings from 1992 to 1999 he was criticized for lack of an animal model. As a result, he adapted the Feeney model of acute traumatic brain injury to chronic brain injury and applied his human protocol of HBOT. Harch and colleagues were able to show in Brain Research that they could improve cognition (spatial learning and memory) while increasing blood vessel density in the damaged hippocampus of the rats.

The potential application to chronic human TBI is important because there is currently no treatment. Chronic TBI affects over 5 million Americans. Costs of treating TBI exceed $60 billion/year in the U.S. alone. The personal toll is far greater. Traumatic brain injury has also been described as the signature injury of the wars in Iraq and Afghanistan. As many as 400,000 U.S. servicemen have been exposed to blast injuries and could have varying degrees of TBI. Application of HBOT to these veterans could have a significant impact on their return to work, quality of life, and national security. For information on the Brain Injury Rescue and Rehabilitation Project, please visit http://www.healthfreedom.net.

Contact:

Brenna Hill, AAHF

Phone: 1.800.230.2762

Email: brenna@healthfreedom.net

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE American Association of Health Freedom
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Researchers Discover Method for Identifying How Cancer Evades the Immune System
4. Researchers Discover Gene For Rare Skin Disorder
5. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Researchers Urge Caution in Using ESAs for Cancer-Related Anemia
11. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):